查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571593

痤瘡藥物市場規模、佔有率、趨勢分析報告：按類型、藥物類別、給藥方法、分銷管道、地區、細分市場預測，2024-2030

Acne Drugs Market Size, Share & Trends Analysis Report By Type (Inflammatory, Non-inflammatory), By Therapeutic Class, By Mode Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

痤瘡藥物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球痤瘡藥物市場規模將達到131.3億美元，2024年至2030年複合年成長率為5.2%。

預計有幾個因素將推動市場發展，包括生技藥品的出現、不健康的生活方式和疾病盛行率的上升。

尋常性痤瘡是最常見的皮膚病之一，影響全球 9.4% 的人。尋常性痤瘡可以發生在任何年齡，但最常見於青少年。研究發現，超過85.0%的12歲至25歲族群有此症狀。痤瘡可以以多種不同的形式出現，從粉刺到囊性病變，這取決於其嚴重程度。

類視色素A和抗生素是痤瘡治療的主要藥物。 2017 年，類視色素在治療層級處於領先地位，預計這一趨勢將持續到 2025 年。由於聯合治療的療效更高、給藥更容易且副作用更少，治療領域正在轉向聯合治療。

從給藥方式來看，目前外用藥物在市場上佔據主導地位。嚴重時採用全身性藥物如口服抗生素、荷爾蒙等藥物。然而，生物製藥（Gevokizumab 和 RA-18C3）的出現可能會加速注射給藥途徑的發展。生物製藥針對具有緩解疾病潛力的發炎機制，使其比傳統的局部治療具有臨床優勢。

由於臨床試驗失敗而停止或終止主要候選藥物是市場面臨的主要阻礙因素。首次推出時，Olumacostat glasaretil（Dermira；一種局部脂質合成抑制劑）預計將成為第一個具有異維A酸樣作用且無明顯副作用的局部抗痤瘡藥物。然而，該藥物未能達到臨床終點，並於 2018 年 3 月停產。同樣，2018 年 7 月，SNA-001（銀奈米粒子溶液）在與 810nm 和 1064nm 雷射結合測試時，在兩項關鍵測試中失敗。由於藥物不可用，Thesan 從 II 期試驗中撤回了 TSN2898。 Xenon 在 II 期臨床試驗失敗後停止了 XEN801 的開發。

儘管痤瘡是世界上最常見的皮膚病之一，但過去十年中痤瘡治療的創新相當有限。製藥公司目前正在探索新的治療方法，例如硬脂醯輔酶A去飽和酶抑制、黑皮質素受體拮抗劑和抗IL-1單株抗體。後期在研發線產品上市在即，預示著全球痤瘡藥物市場前景廣闊。

痤瘡藥物市場報告亮點

  • 發炎痤瘡佔據市場主導地位，2023年佔65.4%的佔有率。此部分的成長要素是導致發炎痤瘡的細菌性皮膚感染疾病。
  • 非處方藥 (OTC) 佔據市場主導地位，2023 年佔 35.9% 的佔有率。
  • 外用藥物領域佔據市場主導地位，2023 年佔 47.5% 的佔有率。此細分市場的成長是由於外用產品的需求不斷增加，因為它們易於使用、劑量準確且可作為非處方藥使用。
  • 零售藥局佔據市場主導地位，2023年佔37.5%的佔有率。
  • 2023年北美痤瘡藥物市場佔據主導地位。痤瘡藥物市場的成長歸因於痤瘡盛行率的上升、醫療保健基礎設施的發展以及涉及痤瘡藥物市場的公司的強大影響力。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章痤瘡藥物市場變數、趨勢和範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 痤瘡藥物市場分析工具
    • 波特的分析
    • PESTEL分析

第4章 痤瘡藥物市場：類型估計與趨勢分析

  • 細分儀表板
  • 痤瘡藥物市場：類型變化分析，2023 年和 2030 年
  • 發炎性痤瘡
  • 非發炎性痤瘡

第5章痤瘡藥物市場：治療層級的估計和趨勢分析

  • 細分儀表板
  • 痤瘡藥物市場：2023 年和 2030 年治療層級變異分析
  • 局部類視色素
  • 口服抗生素
  • 口服類視色素
  • 非處方藥 (OTC)

第6章 痤瘡藥物市場：給藥方式預估及趨勢分析

  • 細分儀表板
  • 痤瘡藥物市場：2023年和2030年給藥方法的變化分析
  • 外用
  • 口服
  • 注射

第7章 痤瘡藥物市場：分銷通路估算及趨勢分析

  • 細分儀表板
  • 痤瘡藥物市場：2023 年和 2030 年分銷管道變化分析
  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 其他

第8章痤瘡藥物市場：區域估計及趨勢分析

  • 痤瘡藥物市場佔有率（按地區），2023 年和 2030 年，
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
  • 拉丁美洲
    • 巴西
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第9章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • GALDERMA
    • Johnson &Johnson Services, Inc.
    • GSK plc.
    • Pfizer Inc.
    • AbbVie Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Bausch Health Companies Inc.
    • Nestle Skin Health SA
    • Bayer AG
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche Ltd
    • LEO Pharma A/S
    • Perrigo Company plc
簡介目錄
Product Code: GVR-2-68038-440-6

Acne Drugs Market Growth & Trends:

The global acne drugs market size is expected to reach USD 13.13 billion by 2030, according to a new report by Grand View Research, Inc., registering a 5.2% CAGR from 2024 to 2030. Several factors such as emergence of biologics, unhealthy lifestyle, and rising disease incidence are anticipated to drive the market.

Acne vulgaris is one of the most common dermatological disorders, affecting 9.4% people worldwide. Although the condition can affect people of all ages, it is most prevalent among teenagers. It has been found that the condition is prevalent in more than 85.0% people between the ages of 12 and 25. Acne can appear in forms ranging from comedones to cystic lesions, depending on its severity.

Retinoids and antibiotics remain the mainstays of acne treatment. Retinoids led the therapeutic classes in 2017, and it is expected to continue this trend through 2025. The therapeutic landscape is witnessing a shift toward combination treatment due to higher efficacy, convenient dosing, and fewer adverse effects.

By mode of administration, topical drugs currently dominate the market. Severe cases see the use of systemic medications such as oral antibiotics, hormonal agents, or other drugs. However, emergence of biologics (Gevokizumab and RA-18C3) will fuel the injectable route of administration. Biologics offer improved clinical advantage over conventional topical treatments since they target inflammatory mechanisms with disease modifying ability.

Discontinuation or termination of key pipeline candidates on account of unsuccessful clinical trials is a major restraint this market faces. Upon launch, Olumacostat glasaretil (Dermira; topical lipid synthesis inhibitor) was expected to be the first topical anti-acne drug with isotretinoin-like results without significant side effects. However, the drug failed to meet clinical endpoints, leading to discontinuation in March 2018. Similarly, SNA-001 (Sienna; silver nanoparticles solution) was deemed unsuccessful in two key trials wherein it was tested in conjunction with 810nm and 1064nm lasers in July 2018. Thesan withdrew TSN2898 from Phase II trials due to drug unavailability. Xenon discontinued development of XEN801 after the drug failed Phase II clinical trials.

Despite being one of the most common dermatological diseases in the world, innovation in acne treatment has been rather limited over the past decade. Drug companies are currently exploring novel treatment approaches including stearoyl CoA desaturase inhibition, melanocortin receptor antagonism, and anti-IL-1 monoclonal antibodies. Impending launch of late-stage pipeline products indicate a promising future for the global acne drugs market.

Acne Drugs Market Report Highlights:

  • Inflammatory acne dominated the market and accounted for a share of 65.4% in 2023. The factors attributing to the growth of the segment are bacterial skin infections that can cause inflammatory acne.
  • Over the counter (OTC) drugs dominated the market and accounted for a share of 35.9% in 2023.
  • Topical segment dominated the market and accounted for a share of 47.5% in 2023. The segment growth can be attributed to rising demand for topical products due to their ease of use, accurate dosage, and high availability as an over-the-counter drug.
  • Retail pharmacies dominated the market and accounted for a share of 37.5% in 2023.
  • North America acne drugs market dominated the market in 2023. The acne drugs market growth is attributed to the rising prevalence of acne, developed healthcare infrastructure, and the strong presence of companies involved in the acne drugs market.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Acne Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Acne Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Acne Drugs Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Acne Drugs Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Inflammatory Acne
    • 4.3.1. Inflammatory Acne Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Non-inflammatory Acne
    • 4.4.1. Non-inflammatory Acne Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Acne Drugs Market: Therapeutic Class Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Acne Drugs Market: Therapeutic Class Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Topical Retinoids
    • 5.3.1. Topical Retinoids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Oral Antibiotics
    • 5.4.1. Oral Antibiotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Oral Retinoids
    • 5.5.1. Oral Retinoids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Over the Counter (OTC) Drugs
    • 5.6.1. Over the Counter (OTC) Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Acne Drugs Market: Mode of Administration Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Acne Drugs Market: Mode of Administration Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Topical
    • 6.3.1. Topical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Injectable
    • 6.5.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Acne Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Acne Drugs Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Retail Pharmacies
    • 7.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Online Pharmacies
    • 7.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Acne Drugs Market: Regional Estimates & Trend Analysis

  • 8.1. Acne Drugs Market Share, By Region, 2023 & 2030, (USD Million)
  • 8.2. North America
    • 8.2.1. North America Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Canada Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Germany Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. France Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. China
      • 8.4.2.1. China Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Japan
      • 8.4.3.1. Japan Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. India Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. South Korea
      • 8.4.5.1. South Korea Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. Australia
      • 8.4.6.1. Australia Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. Saudi Arabia
      • 8.6.2.1. Saudi Arabia Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. UAE
      • 8.6.3.1. UAE Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. South Africa
      • 8.6.4.1. South Africa Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. GALDERMA
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments/ Strategic Initiatives
    • 9.4.2. Johnson & Johnson Services, Inc.
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments/ Strategic Initiatives
    • 9.4.3. GSK plc.
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments/ Strategic Initiatives
    • 9.4.4. Pfizer Inc.
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments/ Strategic Initiatives
    • 9.4.5. AbbVie Inc.
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments/ Strategic Initiatives
    • 9.4.6. Sun Pharmaceutical Industries Ltd.
      • 9.4.6.1. Participant's Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Recent Developments/ Strategic Initiatives
    • 9.4.7. Bausch Health Companies Inc.
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Recent Developments/ Strategic Initiatives
    • 9.4.8. Nestle Skin Health S.A.
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments/ Strategic Initiatives
    • 9.4.9. Bayer AG
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Recent Developments/ Strategic Initiatives
    • 9.4.10. Viatris Inc.
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Recent Developments/ Strategic Initiatives
    • 9.4.11. Teva Pharmaceutical Industries Ltd.
      • 9.4.11.1. Participant's Overview
      • 9.4.11.2. Financial Performance
      • 9.4.11.3. Product Benchmarking
      • 9.4.11.4. Recent Developments/ Strategic Initiatives
    • 9.4.12. F. Hoffmann-La Roche Ltd
      • 9.4.12.1. Participant's Overview
      • 9.4.12.2. Financial Performance
      • 9.4.12.3. Product Benchmarking
      • 9.4.12.4. Recent Developments/ Strategic Initiatives
    • 9.4.13. LEO Pharma A/S
      • 9.4.13.1. Participant's Overview
      • 9.4.13.2. Financial Performance
      • 9.4.13.3. Product Benchmarking
      • 9.4.13.4. Recent Developments/ Strategic Initiatives
    • 9.4.14. Perrigo Company plc
      • 9.4.14.1. Participant's Overview
      • 9.4.14.2. Financial Performance
      • 9.4.14.3. Product Benchmarking
      • 9.4.14.4. Recent Developments/ Strategic Initiatives